Singular Genomics Systems, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OMIC research report →
Companysingulargenomics.com
Singular Genomics Systems, Inc. , a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits.
- CEO
- Andrew Spaventa
- IPO
- 2021
- Employees
- 255
- HQ
- La Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $50.77M
- P/E
- -0.51
- P/S
- 17.44
- P/B
- 0.27
- EV/EBITDA
- -1.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -19.17%
- Op Margin
- -3531.47%
- Net Margin
- -3257.30%
- ROE
- -43.17%
- ROIC
- -39.13%
Growth & Income
- Revenue
- $2.91M · 280.52%
- Net Income
- $-94,820,000 · -7.42%
- EPS
- $-39.08 · -5.00%
- Op Income
- $-102,801,000
- FCF YoY
- 19.87%
Performance & Tape
- 52W High
- $23.41
- 52W Low
- $5.34
- 50D MA
- $19.81
- 200D MA
- $14.23
- Beta
- 1.83
- Avg Volume
- 13.41K
Get TickerSpark's AI analysis on OMIC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 21, 25 | TANG KEVIN | sell | 372,000 |
| Feb 21, 25 | Spaventa Andrew | sell | 5,271 |
| Feb 21, 25 | Spaventa Andrew | sell | 42,881 |
| Feb 21, 25 | Spaventa Andrew | sell | 85 |
| Feb 21, 25 | Spaventa Andrew | sell | 15,555 |
| Feb 21, 25 | Spaventa Andrew | sell | 22,874 |
| Feb 21, 25 | Spaventa Andrew | sell | 33,333 |
| Feb 21, 25 | Meeter Dalen | sell | 6,666 |
| Feb 21, 25 | Meeter Dalen | sell | 1,874 |
| Feb 21, 25 | Meeter Dalen | sell | 6,249 |
Our OMIC Coverage
We haven't published any research on OMIC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OMIC Report →